Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TG Therapeutics, Inc. (TGTX : NSDQ)
 
 • Company Description   
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Number of Employees: 338

 
 • Price / Volume Information   
Yesterday's Closing Price: $36.72 Daily Weekly Monthly
20 Day Moving Average: 1,483,773 shares
Shares Outstanding: 158.76 (millions)
Market Capitalization: $5,829.48 (millions)
Beta: 1.91
52 Week High: $46.48
52 Week Low: $16.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.34% -12.41%
12 Week 0.03% -14.56%
Year To Date 21.99% 14.27%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3020 CARRINGTON MILL BLVD SUITE 475
-
MORRISVILLE,NY 27560
USA
ph: 877-575-8489
fax: 212-554-4531
ir@tgtxinc.com http://www.tgtherapeutics.com
 
 • General Corporate Information   
Officers
Michael S. Weiss - Chairman; Chief Executive Officer and President
Sean A. Power - Chief Financial Officer; Treasurer and Corporate S
Laurence N. Charney - Director
Yann Echelard - Director
Kenneth Hoberman - Director

Peer Information
TG Therapeutics, Inc. (CORR.)
TG Therapeutics, Inc. (RSPI)
TG Therapeutics, Inc. (CGXP)
TG Therapeutics, Inc. (BGEN)
TG Therapeutics, Inc. (GTBP)
TG Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88322Q108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 158.76
Most Recent Split Date: 4.00 (0.02:1)
Beta: 1.91
Market Capitalization: $5,829.48 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.85 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 43.28
Trailing 12 Months: 153.00
PEG Ratio: -
Price Ratios
Price/Book: 24.57
Price/Cash Flow: 306.10
Price / Sales: 15.09
EPS Growth
vs. Year Ago Period: 142.86%
vs. Previous Quarter: -80.00%
Sales Growth
vs. Year Ago Period: 90.40%
vs. Previous Quarter: 11.71%
ROE
06/30/25 - -
03/31/25 - 18.88
12/31/24 - 12.43
ROA
06/30/25 - -
03/31/25 - 7.05
12/31/24 - 4.83
Current Ratio
06/30/25 - -
03/31/25 - 4.02
12/31/24 - 6.25
Quick Ratio
06/30/25 - -
03/31/25 - 3.04
12/31/24 - 5.03
Operating Margin
06/30/25 - -
03/31/25 - 10.13
12/31/24 - 7.11
Net Margin
06/30/25 - -
03/31/25 - 10.13
12/31/24 - 7.11
Pre-Tax Margin
06/30/25 - -
03/31/25 - 10.80
12/31/24 - 7.78
Book Value
06/30/25 - -
03/31/25 - 1.49
12/31/24 - 1.43
Inventory Turnover
06/30/25 - -
03/31/25 - 0.45
12/31/24 - 0.43
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.03
12/31/24 - 1.10
Debt-to-Capital
06/30/25 - -
03/31/25 - 50.77
12/31/24 - 52.36
 

Powered by Zacks Investment Research ©